CATEGORY : Biomarkers

Life Science Market Reports

Our life science market intelligence products have been recognized by market insiders and outsiders alike for their accuracy, in-depth analysis, and unique insights.

Market Reports

I/O Biomarker Spotlight: Digital Pathology and Multiplex Spatial Tissue Analysis

We’ve noticed a trend in the oncology biomarker this year.  Both anecdotally, through our observations and discussions at AGBT and AACR and with our network of industry KOLs, and analytically,

An Updated Look at TMB: What Has Changed and What to Expect

Since we last reported on the rise of tumor mutational burden (TMB) in immuno-oncology (I/O) a year ago, there have been numerous material developments of this biomarker in the I/O

AACR 2019: DeciBio Highlights

A month ago, we attended AGBT 2019 and observed a strong interest in spatial profiling and single cell analysis. While we recognize that we are somewhat biased by the in-person

Pulse Survey: Adoption and Utilization of Next Generation Cancer Biomarkers

The way cancer is diagnosed, treated, and monitored is changing more rapidly than ever. In 2019, we expect there to be catalysts that fundamentally change cancer companion diagnostic biomarker testing

Three lessons for digital health entrepreneurs from #RHSUM18

This year’s Rock Health annual digital health summit showcased another impressive lineup, with speakers like Bernard Tyson (CEO of Kaiser Permanente), Toby Cosgrove (Executive Adviser for Google Cloud and former

The Implications and Benefits of Early Identification of Alzheimer’s Disease

Editor’s Note: This article was written by Trpti Sanghvi, who was part of DeciBio’s summer 2018 intern class. She will graduate in Spring 2019 with a degree in Neuroscience. Alzheimer’s

AGBT Precision Health 2018 Highlights: Precision Medicine Builds Up Steam Outside Academia

We attended AGBT Precision Health and had a chance to speak with pathologists, researchers, tools manufacturers, and other precision medicine stakeholders and thought leaders. The conference is finding its identity, as

From Trial to Drug Label: Identifying the Next Wave of Oncology Biomarkers

Characterizing the hallmarks of trials that have led to biomarker label expansions Molecular biomarkers serve as a sorting factor by which oncology patients can be divided into sub-populations that are

New CRISPR Companies Heat Up as Skepticism Grows

Novel ways of harnessing CRISPR disrupt diagnostics, therapeutics, and food systems While much hype has been built around CRISPR-Cas9 and its ability to revolutionize treatment of genetic disorders and disease,